Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2466

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? ; volume:11 ; number:1 ; day:23 ; month:5 ; year:2011 ; pages:1-4 ; date:12.2011
BMC pulmonary medicine ; 11, Heft 1 (23.5.2011), 1-4, 12.2011

Creator: Hennigs, Jan Kristoff

Contributor: Amsberg, Gunhild von
Baumann, Hans Jörg
Honecker, Friedemann
Kluge, Stefan
Bokemeyer, Carsten
Brümmendorf, Tim Henrik
Klose, Hans
SpringerLink (Online service)

DOI: 10.1186/1471-2466-11-30

URN: urn:nbn:de:1111-2016071616702

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Other Objects (12)

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Editorial: Targeting bruton tyrosine kinase

Pulmonary capillary pressure in pulmonary hypertension

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib

Newer Tyrosine Kinase Inhibitors for CML

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Editorial: Targeting bruton tyrosine kinase

Pulmonary capillary pressure in pulmonary hypertension

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib

Newer Tyrosine Kinase Inhibitors for CML

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Editorial: Targeting bruton tyrosine kinase

Pulmonary capillary pressure in pulmonary hypertension

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib

Newer Tyrosine Kinase Inhibitors for CML

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Editorial: Targeting bruton tyrosine kinase

Pulmonary capillary pressure in pulmonary hypertension

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib

Newer Tyrosine Kinase Inhibitors for CML

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Editorial: Targeting bruton tyrosine kinase

Pulmonary capillary pressure in pulmonary hypertension

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib

Newer Tyrosine Kinase Inhibitors for CML

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Editorial: Targeting bruton tyrosine kinase

Pulmonary capillary pressure in pulmonary hypertension

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib

Newer Tyrosine Kinase Inhibitors for CML

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report

Targeting tumour microenvironment by tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitors- current status

Related objects

Reset password